Danny McBryan

Statistics

Publications

Citations

363

H-Index

Active since

2013

Affiliations

Novartis (Switzerland)(Current)

Tris Pharma (United States)

Novartis (United States)

Novartis (United Kingdom)

Danny McBryan is an author at Novartis (Switzerland) specializing in chronic obstructive pulmonary disease, pharmacotherapy, and obstructive lung disease.

Publications per year

2013–2014

Publications

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

Marc Decramer, Kenneth R. Chapman, Ronald Dahl et al. · The Lancet Respiratory Medicine · 2013 · 275 citations

Medicine, Clinical Sciences, Pharmacotherapy +9

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

Walter Vincken, Joseph Aumann, Hungta Chen et al. · International Journal of COPD · 2014 · 75 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity

Donald A. Mahler, Roland Buhl, David Lawrence et al. · Pulmonary Pharmacology & Therapeutics · 2013 · 13 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

1–3 of 3